<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report on 18 months of experience with <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> (Cy A) in allogeneic bone marrow transplantation for severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty-three patients treated with Cy A for postgraft immunosuppression are described and compared with 14 similar patients with SAA in whom <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX) was used </plain></SENT>
<SENT sid="2" pm="."><plain>The early results are encouraging with 73% survival in the Cy A group compared with 43% in the MTX group </plain></SENT>
<SENT sid="3" pm="."><plain>The improvement is partly attributable to the low incidence of graft failure </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> (GVHD) remains a problem with an overall incidence of 70% in Cy A-treated aplastic patients, although mortality has been ony 14% </plain></SENT>
<SENT sid="5" pm="."><plain>Toxicity attributable to Cy A has so far been acceptable and nephrotoxicity is usually mild and reversible </plain></SENT>
<SENT sid="6" pm="."><plain>However, three aplastic patients have developed clinically significant <z:e sem="disease" ids="C0341697" disease_type="Disease or Syndrome" abbrv="">renal impairment</z:e> while receiving both Cy A and <z:chebi fb="0" ids="22507">aminoglycoside antibiotics</z:chebi> </plain></SENT>
</text></document>